loading
Achilles Therapeutics Plc Adr stock is traded at $1.12, with a volume of 63,351. It is down -0.88% in the last 24 hours and down -5.08% over the past month. Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
See More
Previous Close:
$1.13
Open:
$1.14
24h Volume:
63,351
Relative Volume:
0.38
Market Cap:
$46.18M
Revenue:
-
Net Income/Loss:
$-66.88M
P/E Ratio:
-0.6788
EPS:
-1.65
Net Cash Flow:
$-62.91M
1W Performance:
-2.05%
1M Performance:
-5.08%
6M Performance:
+39.98%
1Y Performance:
+25.84%
1-Day Range:
Value
$1.105
$1.14
1-Week Range:
Value
$1.10
$1.16
52-Week Range:
Value
$0.63
$1.76

Achilles Therapeutics Plc Adr Stock (ACHL) Company Profile

Name
Name
Achilles Therapeutics Plc Adr
Name
Phone
-
Name
Address
-
Name
Employee
215
Name
Twitter
Name
Next Earnings Date
2024-12-11
Name
Latest SEC Filings
Name
ACHL's Discussions on Twitter

Compare ACHL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ACHL
Achilles Therapeutics Plc Adr
1.12 46.18M 0 -66.88M -62.91M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
438.40 113.67B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
683.08 74.97B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
665.68 40.50B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
277.16 35.95B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
120.88 29.63B 3.30B -501.07M 1.03B -2.1146

Achilles Therapeutics Plc Adr Stock (ACHL) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-05-24 Downgrade Piper Sandler Overweight → Neutral
Apr-26-21 Initiated BofA Securities Buy
Apr-26-21 Initiated Chardan Capital Markets Buy
Apr-26-21 Initiated JP Morgan Underweight
Apr-26-21 Initiated Oppenheimer Outperform
Apr-26-21 Initiated Piper Sandler Overweight
View All

Achilles Therapeutics Plc Adr Stock (ACHL) Latest News

pulisher
Dec 29, 2024

Head to Head Review: OPHIR ENERGY PL/ADR (OTCMKTS:OPHRY) vs. HOYA (OTCMKTS:HOCPY) - Defense World

Dec 29, 2024
pulisher
Dec 24, 2024

Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - GlobeNewswire Inc.

Dec 24, 2024
pulisher
Oct 16, 2024

80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港

Oct 16, 2024
pulisher
Sep 23, 2024

ACHL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Sep 23, 2024
pulisher
Sep 23, 2024

Check Out Achilles Therapeutics Plc ADR (ACHL)’s Trade Data Rather Than the Analysts’ Views - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Sep 23, 2024
pulisher
Sep 20, 2024

why Achilles Therapeutics Plc ADR [ACHL] is a Good Choice for Investors After New Price Target of $1.25 - The DBT News

Sep 20, 2024
pulisher
Sep 20, 2024

What Analysts Were Expecting After PowerFleet Inc (NASDAQ: AIOT) rose 2.40% - Stocks Register

Sep 20, 2024
pulisher
Sep 20, 2024

Achilles Thera shifts focus to new cancer treatment avenues - The Pharma Letter

Sep 20, 2024
pulisher
Sep 19, 2024

Achilles Therapeutics ends TIL-based cancer therapy trials - Investing.com

Sep 19, 2024
pulisher
Sep 19, 2024

You Should Read This Analysis Before Investing in Achilles Therapeutics Plc ADR (NASDAQ:ACHL) - US Post News

Sep 19, 2024
pulisher
Sep 19, 2024

Achilles stock climbs on strategic focus (NASDAQ:ACHL) - Seeking Alpha

Sep 19, 2024
pulisher
Sep 19, 2024

Achilles Therapeutics Announces Strategic Update - Yahoo Finance

Sep 19, 2024
pulisher
Aug 14, 2024

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - GlobeNewswire

Aug 14, 2024
pulisher
May 22, 2024

Achilles Therapeutics Announces Research Collaboration with - GlobeNewswire

May 22, 2024
pulisher
May 17, 2024

Achilles Therapeutics faces Nasdaq delisting over share price - Investing.com

May 17, 2024
pulisher
Feb 09, 2024

Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Feb 09, 2024
pulisher
Jan 24, 2024

Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Jan 24, 2024
pulisher
Nov 13, 2023

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights - GlobeNewswire

Nov 13, 2023
pulisher
Oct 24, 2023

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis - Yahoo Finance

Oct 24, 2023
pulisher
Nov 01, 2022

What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock - Yahoo Finance

Nov 01, 2022
pulisher
Sep 07, 2022

IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study - Yahoo Finance

Sep 07, 2022
pulisher
Sep 05, 2022

Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104 - Yahoo Finance

Sep 05, 2022
pulisher
Aug 23, 2022

Novo (NVO) Posts Positive Data From Diabetes Study on CagriSema - Nasdaq

Aug 23, 2022
pulisher
Dec 24, 2021

Achilles Therapeutics PlcADR Shares Close the Day 10.1% HigherDaily Wrap - Nasdaq

Dec 24, 2021
pulisher
Mar 30, 2021

Achilles Therapeutics Announces Pricing of Initial Public Offering - GlobeNewswire

Mar 30, 2021
pulisher
Jul 27, 2011

ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN

Jul 27, 2011

Achilles Therapeutics Plc Adr Stock (ACHL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$352.30
price down icon 5.49%
$41.04
price up icon 0.79%
$22.36
price up icon 3.33%
$5.41
price up icon 3.84%
biotechnology ONC
$226.89
price up icon 0.08%
$120.88
price down icon 0.23%
Cap:     |  Volume (24h):